AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 223 filers reported holding AMICUS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $287,011 | -6.0% | 23,603 | -2.9% | 0.00% | – |
| Q2 2023 | $305,321 | -16.2% | 24,309 | -26.1% | 0.00% | -100.0% |
| Q1 2023 | $364,562 | -3.9% | 32,873 | +5.8% | 0.00% | 0.0% |
| Q4 2022 | $379,255 | -23.8% | 31,061 | -34.7% | 0.00% | 0.0% |
| Q3 2022 | $498,000 | -5.9% | 47,559 | -3.5% | 0.00% | 0.0% |
| Q2 2022 | $529,000 | +269.9% | 49,292 | +227.5% | 0.00% | – |
| Q1 2022 | $143,000 | +14200.0% | 15,049 | +16809.0% | 0.00% | – |
| Q4 2021 | $1,000 | -99.0% | 89 | -99.2% | 0.00% | – |
| Q3 2021 | $104,000 | -18.1% | 10,907 | -17.3% | 0.00% | – |
| Q2 2021 | $127,000 | +14.4% | 13,182 | +17.4% | 0.00% | – |
| Q1 2021 | $111,000 | +1485.7% | 11,227 | +3408.4% | 0.00% | – |
| Q4 2020 | $7,000 | +133.3% | 320 | +53.1% | 0.00% | – |
| Q3 2020 | $3,000 | 0.0% | 209 | 0.0% | 0.00% | – |
| Q2 2020 | $3,000 | -25.0% | 209 | -51.2% | 0.00% | – |
| Q1 2020 | $4,000 | -33.3% | 428 | -29.0% | 0.00% | – |
| Q4 2019 | $6,000 | -90.2% | 603 | -87.7% | 0.00% | – |
| Q2 2019 | $61,000 | +38.6% | 4,896 | +50.9% | 0.00% | – |
| Q1 2019 | $44,000 | +528.6% | 3,245 | +365.6% | 0.00% | – |
| Q4 2018 | $7,000 | -41.7% | 697 | -14.4% | 0.00% | – |
| Q1 2018 | $12,000 | 0.0% | 814 | -0.4% | 0.00% | – |
| Q4 2017 | $12,000 | 0.0% | 817 | +0.5% | 0.00% | – |
| Q3 2017 | $12,000 | – | 813 | +1013.7% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 73 | -98.5% | 0.00% | – |
| Q3 2016 | $36,000 | +38.5% | 4,805 | 0.0% | 0.00% | – |
| Q2 2016 | $26,000 | -36.6% | 4,805 | 0.0% | 0.00% | – |
| Q1 2016 | $41,000 | -12.8% | 4,805 | 0.0% | 0.00% | – |
| Q4 2015 | $47,000 | -29.9% | 4,805 | 0.0% | 0.00% | – |
| Q3 2015 | $67,000 | -57.1% | 4,805 | -56.5% | 0.00% | -100.0% |
| Q2 2015 | $156,000 | +24.8% | 11,045 | -3.6% | 0.00% | – |
| Q1 2015 | $125,000 | +16.8% | 11,455 | -10.8% | 0.00% | – |
| Q4 2014 | $107,000 | – | 12,845 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |